Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PPAR-gamma agonists and diabetic nephropathy.

Literature DB >> 16316600

PPAR-gamma agonists and diabetic nephropathy.

Abstract

Diabetic nephropathy is a clinical syndrome of albuminuria, declining glomerular filtration rate, and increased risk of cardiovascular disease. Multiple mechanisms have been implicated in its pathogenesis. Although current therapies appear to be effective, treatment of diabetic nephropathy remains suboptimal. This review summarizes the recently emerging evidence suggesting that peroxisome proliferator-activated receptor-gamma agonists may prove to be effective therapeutic agents in the treatment of diabetic renal complications.

Entities: Disease Gene

Mesh：

Substances：

Year: 2005 PMID： 16316600 DOI： 10.1007/s11892-005-0057-5

Source DB: PubMed Journal: Curr Diab Rep ISSN： 1534-4827 Impact factor: 4.810

59 in total

1. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation.

Authors: Feng Zheng; Alessia Fornoni; Sharon J Elliot; Youfei Guan; Matthew D Breyer; Liliane J Striker; Gary E Striker
Journal: Am J Physiol Renal Physiol Date: 2002-04

2. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

Authors: Robert Earl Routh; John Hardwick Johnson; Kevin John McCarthy
Journal: Kidney Int Date: 2002-04 Impact factor: 10.612

3. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Authors: Hui Zhang; Aihua Zhang; Donald E Kohan; Raoul D Nelson; Frank J Gonzalez; Tianxin Yang
Journal: Proc Natl Acad Sci U S A Date: 2005-06-14 Impact factor: 11.205

4. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.

Authors: T Nakamura; C Ushiyama; N Shimada; K Hayashi; I Ebihara; H Koide
Journal: J Diabetes Complications Date: 2000 Sep-Oct Impact factor: 2.852

5. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells.

Authors: Zuying Xiong; Haichang Huang; Jingzi Li; Youfei Guan; Haiyan Wang
Journal: Ren Fail Date: 2004-09 Impact factor: 2.606

6. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney.

Authors: T Yang; D E Michele; J Park; A M Smart; Z Lin; F C Brosius; J B Schnermann; J P Briggs
Journal: Am J Physiol Date: 1999-12

7. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

Authors: Frank Pistrosch; Kay Herbrig; Beate Kindel; Jens Passauer; Sabine Fischer; Peter Gross
Journal: Diabetes Date: 2005-07 Impact factor: 9.461

8. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature.

Authors: Y Guan; Y Zhang; A Schneider; L Davis; R M Breyer; M D Breyer
Journal: Am J Physiol Renal Physiol Date: 2001-12

9. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

Authors: H Satoh; K Tsukamoto; Y Hashimoto; N Hashimoto; M Togo; M Hara; H Maekawa; N Isoo; S Kimura; T Watanabe
Journal: Biochem Biophys Res Commun Date: 1999-01-27 Impact factor: 3.575

Review 10. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

Authors: Sunder Mudaliar; Anna R Chang; Robert R Henry
Journal: Endocr Pract Date: 2003 Sep-Oct Impact factor: 3.443

7 in total

PPAR-gamma agonists and diabetic nephropathy.

1. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation.

2. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.

3. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

4. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.

5. Anti-inflammatory effect of PPARgamma in cultured human mesangial cells.

6. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney.

7. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients.

8. Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature.

9. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function.

Review 10. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

1. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1.

Review 2. Nuclear receptors in the kidney during health and disease.

3. Rosiglitazone increases cerebral klotho expression to reverse baroreflex in type 1-like diabetic rats.

Review 4. The Role of Peroxisome Proliferator-Activated Receptors in Kidney Diseases.

5. Peroxisome Proliferator-Activated Receptor Gene Knockout Promotes Podocyte Injury in Diabetic Mice.

6. Gamma linolenic acid exerts anti-inflammatory and anti-fibrotic effects in diabetic nephropathy.

7. PPARs and Female Reproduction: Evidence from Genetically Manipulated Mice.